Loading BAX detail
Loading ticker data...
Loading BAX detail
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide.
The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules.
Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
Chart data unavailable
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medtech company, will host a conference call to discuss its first-quarter 2026 financial results on Thursday, April 30, 2026 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://registrations.events/direct/Q4I946023356 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.
Shares of Baxter International Inc. (NYSE: BAX - Get Free Report) have been assigned a consensus rating of "Hold" from the thirteen analysts that are presently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and two have assigned a buy rating to
Baxter International (NYSE: BAX - Get Free Report) and Zynex (NASDAQ: ZYXI - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability and dividends. Insider and Institutional Ownership 90.2% of Baxter International shares
BAX introduces the IV Verify system to improve IV labeling accuracy, targeting medication safety gaps and boosting workflow efficiency in clinical settings.
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), an innovative leader in infusion therapies and platforms, today debuted the IV Verify Line Labeling System, an automated solution, at the 2026 American Organization for Nursing Leadership Conference. The IV Verify system is designed to streamline nursing workflows, save clinician time and support safer medication administration at the bedside. Baxter's launch of the product is the result of a strategic and exclusive distrib.
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will host its Annual Meeting of Stockholders (the 2026 Annual Meeting) in a virtual format on Tuesday, May 5, 2026 at 9 a.m., Central Time, as disclosed in Baxter's proxy statement for the 2026 Annual Meeting. Online access to the 2026 Annual Meeting will begin at 8:45 a.m., Central Time. Stockholders will not be able to attend the 2026 Annual Meeting in person. The virtual format provides a safe, c.
Largest Single Investment from a Corporate Foundation Aims to Strengthen Healthcare Resilience by Advancing Therapy Animal Visits in U.S. Healthcare Settings BELLEVUE, Wash. and DEERFIELD, Ill.
The European Union's medicines regulator said on Tuesday it expects Baxter International's cancer drugs containing ifosfamide will remain in shortage in the bloc well into the first quarter of next year.
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced the departure of executive vice president and chief financial officer (CFO) Joel Grade. Mr. Grade is leaving the company to prioritize family matters but will continue in an advisory capacity until April 30, 2026. Baxter has named Anita Zielinski as interim CFO, effective immediately, while the company conducts its search to fill the role. Ms. Zielinski joined Baxter in 2025 as senio.
Baxter International Inc. (BAX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Baxter International faces deep investor skepticism after disappointing guidance and management's decision to delay its Investor Day. Recent leadership changes and a flattened organizational structure are part of a turnaround effort, which is off to an admittedly bumpy start. But valuation is reasonable enough that BAX is a straight bet on the turnaround working.
Baxter International Inc. (BAX) Presents at Citi's 2026 Unplugged MedTech and Life Sciences Access Day Transcript
Our largest new purchase was Houston-headquartered Prosperity BancShares, the fifth-largest bank in Texas. Another notable purchase was Union Pacific, the largest freight railroad in the US. Besides our sale of Baxter International, we also exited LKQ, a vehicle parts distributor.
Baxter International Inc. (NYSE: BAX - Get Free Report) has been assigned a consensus rating of "Reduce" from the fourteen research firms that are currently covering the company, MarketBeat.com reports. Three equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and two have assigned a buy rating to
Acquired 2,074,016 shares of Baxter International Inc; estimated trade value $39.63 million based on quarterly average prices Quarter-end position value rose by $39.63 million, reflecting both new shareholdings and price movement over the period Transaction resulted in a position representing 2.66% of 13F reportable assets under management (AUM) Position at quarter-end: 2,074,016 shares valued at $39.63 million This new stake represents 2.66% of fund AUM, placing it outside the fund's top five holdings We're bullish on these 10 stocks ›
